Here, DNA repair inhibitors (e.g., PARP or APE1 inhibitors) might be beneficial by inducing synthetic lethality in DNA repair defective TKI-refractory CML cells [31] and may constitute possible treatment options. Here, APEX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.